Total Payments
$2,523
2023 Payments
$1,464
Companies
7
Transactions
22
Medicare Patients
841
Medicare Billing
$192,625
Payment Breakdown by Category
Consulting$1,250 (49.5%)
Other$1,098 (43.5%)
Food & Beverage$162.79 (6.5%)
Education$11.92 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,250 | 1 | 49.5% |
| Long term medical supply or device loan | $1,098 | 12 | 43.5% |
| Food and Beverage | $162.79 | 8 | 6.5% |
| Education | $11.92 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $1,262 | 2 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,115 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $67.16 | 3 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.40 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $20.91 | 1 | $0 (2017) |
| Incyte Corporation | $18.32 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,464 | 5 | PFIZER INC. ($1,250) |
| 2022 | $353.25 | 5 | Novartis Pharmaceuticals Corporation ($333.32) |
| 2021 | $610.12 | 7 | Novartis Pharmaceuticals Corporation ($598.20) |
| 2019 | $46.72 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($28.40) |
| 2018 | $11.66 | 1 | PFIZER INC. ($11.66) |
| 2017 | $37.25 | 2 | E.R. Squibb & Sons, L.L.C. ($20.91) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2023 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 02/16/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Oncology | ||||||
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 12/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Oncology | ||||||
| 06/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 01/15/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $28.40 | General |
| 11/14/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.32 | General |
| Category: Hematology/Oncology | ||||||
| 03/07/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2017 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), KISQALI | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.91 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 112 | 154 | $69,219 | $18,670 |
| 2022 | 4 | 207 | 451 | $158,883 | $48,832 |
| 2021 | 7 | 287 | 602 | $212,938 | $65,968 |
| 2020 | 6 | 235 | 670 | $239,389 | $59,154 |
Total Patients
841
Total Services
1,877
Medicare Billing
$192,625
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 50 | $29,617 | $7,721 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $18,088 | $4,715 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 36 | $13,680 | $4,214 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 22 | $5,632 | $1,450 | 25.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 20 | 21 | $2,202 | $570.57 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 86 | 287 | $109,060 | $33,771 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 99 | $25,344 | $7,729 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 24 | 24 | $13,368 | $3,774 | 28.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 41 | $11,111 | $3,558 | 32.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 115 | 378 | $143,640 | $45,940 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 70 | 91 | $23,296 | $6,598 | 28.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 34 | 34 | $18,938 | $5,470 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 53 | $14,363 | $4,465 | 31.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $7,147 | $2,076 | 29.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 17 | 17 | $3,910 | $943.50 | 24.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 14 | 17 | $1,644 | $476.49 | 29.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 96 | 458 | $174,040 | $42,304 | 24.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 77 | 130 | $33,280 | $7,755 | 23.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $13,368 | $3,109 | 23.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 34 | $9,214 | $2,844 | 30.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $7,147 | $1,958 | 27.4% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 11 | 12 | $2,340 | $1,184 | 50.6% |
About Dr. Niki Tank, MD
Dr. Niki Tank, MD is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2009. The National Provider Identifier (NPI) number assigned to this provider is 1629308515.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Niki Tank, MD has received a total of $2,523 in payments from pharmaceutical and medical device companies, with $1,464 received in 2023. These payments were reported across 22 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($1,250).
As a Medicare-enrolled provider, Tank has provided services to 841 Medicare beneficiaries, totaling 1,877 services with total Medicare billing of $192,625. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Pasadena, CA
- Active Since 12/28/2009
- Last Updated 04/17/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629308515
Products in Payments
- IBRANCE (Drug) $1,262
- KISQALI (Drug) $931.52
- ENHERTU (Biological) $42.85
- SAPHNELO (Biological) $24.31
- OPDIVO (Biological) $20.91
- JAKAFI (Drug) $18.32
- AFINITOR (Drug) $16.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Pasadena
Dr. Yuan Yuan, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $523,801
Internal Medicine $523,801
Christopher Dagher, M.d, M.D
Internal Medicine — Payments: $103,615
Internal Medicine $103,615
Peter Haddad, M.d, M.D
Internal Medicine — Payments: $87,600
Internal Medicine $87,600
Dr. Andrew Williams, M.d, M.D
Internal Medicine — Payments: $85,273
Internal Medicine $85,273
Joseph Dellinger, Md, MD
Internal Medicine — Payments: $77,175
Internal Medicine $77,175
Dr. Helen Moon, M.d, M.D
Internal Medicine — Payments: $61,882
Internal Medicine $61,882